866-997-4948(US-Canada Toll Free)

Estrogen Receptor Positive (ER+) Breast Cancer - Market Insights, Epidemiology and Market Forecast-2023-United States

Published By :

DelveInsight

Published Date : Jul 2016

Category :

Cancer

No. of Pages : 60 Pages

DelveInsights Estrogen Receptor Positive (ER+) Breast Cancer - Market Insights, Epidemiology and Market Forecast-2023- US Reports provides an overview of the disease and global market size of the Estrogen Receptor Positive (ER+) Breast Cancer for the United States. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Estrogen Receptor Positive (ER+) Breast Cancer from 2013-2023. According to DelveInsight, the forecasted patient population of ER+ breast cancer will increase at a CAGR of 2.03% from 2015 to 2023 and the worldwide ER+ breast cancer market is estimated to be 2.86 billion by 2023. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Note: This report will be delivered to the client in 48 hours

Scope
Report covers the disease overview, current treatment options, prescription drugs and emerging therapies.
The Report also covers the detailed global historical and forecasted epidemiological data covering United States from 2013-2023.
It also provides Market size of Estrogen Receptor Positive (ER+) Breast Cancer for United States and forecasted Market size to 2023.

Table of Contents

1 Report Introduction
2 Executive Summary
Key Findings
3 ER+ Breast Cancer Market Overview at a Glance
Worldwide Market Size of ER+ Breast Cancer in 2013
Worldwide Market Size of ER+ Breast Cancer in 2023
4 Treatment Landscape
Treatment Options by Stage
Stage IA
Stage IB
Stage IC
Stage IIA
Stage IIB, Stage IIC, Stage IIIA, Stage, IIIB, Stage IIIC, Stage IV
Treatment Algorithm
Treatment Follow-Up
5 Epidemiology and Patient Population
Key Findings
Overview
Disease Classification
Population and Forecast Methodology
Total Incident Cases
Diagnosed Drug Treated Population
Percentage Diagnosed
Percentage Drug Treated
6 Current Medical Practice and Therapies in Use
Key Findings
Overview of ER+ Breast Cancer
Treatment Goals
Currently Medical Practice
Overview of ER+ Breast Cancer Drug Classification
Prescription Drugs, Dosing & Route
7 Emerging Therapies
Key Findings
Unmet need
Late Stage Pipeline Overview
Expected Launch date of these therapies in United States
Late Stage Pipeline Analysis
Efficacy & Safety Results
8 United States Market Assessment
Key Findings
United States Market Forecast
United States Market Size
Market Driver and Constraints
Factors Driving the Market for ER+ Breast Cancer
Factors Constraining the Market for ER+ Breast Cancer
9 Consulting Services
10 Disclaimer
11 About DelveInsight

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *